Researchers sought to determine the optimal ADC sequence strategy for the treatment of HER2-positive metastatic breast cancer. Retrospective, real-world study demonstrated that the optimal ADC sequence for HER2-positive metastatic breast cancer is T-Dxd followed by RC48.